Neurogranulin (Ng) is a postsynaptic protein correlating with cognitive reserve. Low Ng indicates depleted neuronal capacity to produce p-tau217, making CSF p-tau217 unreliable. Patients with preserved Ng levels show faithful p-tau217 response to amyloid modulation. This hypothesis addresses a potentially critical prerequisite for valid p-tau217 endpoints but remains the lowest-confidence proposal requiring prospective validation.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Neurogranulin NRGN expression level"] --> B["Intact neuronal reserve capacity index"]
B --> C["Favorable amyloid modulation response profile"]
C --> D["Reliable CSF p-tau217 as Alzheimer's progression marker"]
D --> E["Accurate patient stratification for anti-amyloid therapy"]
Median TPM across 13 brain regions for NRGN from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
3
1
MECH 1CLIN 3GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
CSF Ng declines with AD progression and correlates…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we compare longitudinal CSF p-tau217 measurements (baseline, 6 months, 12 months) in amyloid-positive patients with low CSF Ng (below 25th percentile) versus preserved CSF Ng (above 75th percentile) who receive no disease-modifying treatment, THEN the preserved Ng group will show higher test-retest reliability (ICC >0.85) while the low Ng group will show poor reliability (ICC <0.60), indicating that low Ng depletes neuronal capacity to produce consistent p-tau217.
pendingconf: 0.18
Expected outcome: Preserved Ng group ICC: 0.89 (95% CI: 0.82-0.94); Low Ng group ICC: 0.52 (95% CI: 0.38-0.67); CV in low Ng group >20% vs <8% in preserved Ng group
Falsified by: If the low Ng group demonstrates ICC >0.75 and CV <10%, equivalent to the preserved Ng group, the hypothesis that Ng identifies patients with unreliable p-tau217 is disproven
Method: Prospective single-center cohort study enrolling 120 amyloid-positive (CSF Aβ42/Aβ40 ratio + Florbetapir PET) early-stage AD patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI) or equivalent multi-site cohort with standardized CSF collection protocols
IF we stratify amyloid-positive early Alzheimer's disease patients by baseline CSF neurogranulin (Ng) levels into high (upper tertile) and low (lower tertile) groups AND administer an amyloid-targeting monoclonal antibody (lecanemab or donanemab) for 18 months, THEN the high Ng group will exhibit a significantly greater reduction in CSF p-tau217 (≥40% decrease from baseline) compared to the low Ng group (<20% decrease), reflecting faithful p-tau217 response in patients with intact neuronal reserve.
pendingconf: 0.15
Expected outcome: High Ng group: mean CSF p-tau217 reduction of 45% (95% CI: 38-52%); Low Ng group: mean CSF p-tau217 reduction of 12% (95% CI: 5-19%); between-group difference p<0.001
Falsified by: If both Ng groups demonstrate equivalent mean CSF p-tau217 reduction (±5% of each other) at 18 months, the hypothesis that Ng predicts p-tau217 reliability is disproven
Method: Secondary analysis of the CLARITY-AD (lecanemab) or TRAILBLAZER-ALZ (donanemab) phase 3 trials, selecting amyloid-positive participants with available baseline CSF Ng and p-tau217 measurements, stratified by Ng tertiles
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
NRGN — Search for structure
Click to search RCSB PDB